BMC Surgery

Table 3 Prognostic value of Cystatin SN expression in 209 ESCC patients

From: Overexpression of Cystatin SN positively affects survival of patients with surgically resected esophageal squamous cell carcinoma

Cystatin SN		DFS (months)			OS (months)
expression	Cases	Mean	Median	P-value^*	Mean	Median	P-value^*
Total	209			< 0.001			< 0.001
Low expression	145	52	28		57	33
High expression	64	94	NR		100	NR
pT status				0.001			0.001
pT1-2	66
Low expression	43	56	29		60	35
High expression	23	108	NR		110	NR
pT3-4	143			0.003			0.001
Low expression	102	49	25		54	26
High expression	41	73	NR		80	NR
pN status
pN0	116			< 0.001			< 0.001
Low expression	76	70	67		75	72
High expression	40	118	NR		118	NR
PN1-3	93			0.058			0.017
Low expression	69	29	18		34	21
High expression	24	44	27		53	42
pTNM
Stage II	133			< 0.001			< 0.001
Low expression	88	67	56		72	67
High expression	45	117	NR		117	NR
Stage III	76			0.336			0.099
Low expression	57	27	11		31	19
High expression	19	34	26		45	40
Differentiation
G1	56			0.003			0.001
Low expression	39	67	66		71	67
High expression	17	106	NR		110	NR
G2	105			0.001			0.002
Low expression	68	49	28		54	35
High expression	37	92	NR		94	NR
G3	48			0.604			0328
Low expression	38	37	22		43	25
High expression	10	49	17		60	23

^*Log-rank test.
DFS disease-free survival, OS overall survival, pT pathologic tumor, pN pathologic node, pTNM pathologic tumor-node-metastasis, G tumor grade, NR not reached.

Back to article page

ISSN: 1471-2482

Contact us

Submission enquiries: bmcsurgery@biomedcentral.com
General enquiries: ORSupport@springernature.com